January 30, 2023

January 30, 2023

Ask Me Anything – Featuring Dr. Brian Hill and Jeff Folloder

Dr. Brian Hill joins us for CLL Society’s Facebook Live Event “Ask Me Anything”. With no prepared presentation, this event is truly dedicated to answering your questions. Dr. Brian Hill is Director of the Lymphoid Malignancies Program at Cleveland Clinic Taussig Cancer Institute and a member of CLL Society’s

January 30, 2023

CLL Society Organizes Joint Effort Urging Government Agencies to Focus on Continued COVID-19 for the Immunocompromised

In light of the FDA’s announcements regarding the discontinuation of Emergency Use Authorization for both Evusheld and Bebtelovimab, CLL Society and eight other patient advocacy organizations sent a letter to federal officials requesting them to immediately undertake thirteen specific actions that would help protect the estimated seven million Americans

January 30, 2023

CLL Society’s COVID-19 Update for the Week of January 30, 2023

Here is your weekly summary of what has been happening this past week of January 30, 2023 in the United States.

January 30, 2023

FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

On 1/27/23 [email protected] announced the Federal Drug Administration (FDA)’s accelerated approval of pirtobrutinib in adult patients with relapsed or refractory mantle cell lymphoma (MCL) following at least 2 lines of systemic therapy, including a BTK inhibitor.

January 30, 2023

FDA Announces Evusheld is Not Currently Authorized for Emergency Use in the U.S.

As of 1/26/23, Evusheld (tixagevimab co-packaged with cilgavimab) is no longer available as Pre-Exposure Prophylaxis (PrEP) in the United States. That decision was made because as the virus continued to mutate, now over 90% of SARS-CoV-2 variants of concerns (VOC) circulating in the U.S. are no longer believed to

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

January 30, 2023

Ask Me Anything – Featuring Dr. Brian Hill and Jeff Folloder

CLL Society Organizes Joint Effort Urging Government Agencies to Focus on Continued COVID-19 for the Immunocompromised

CLL Society’s COVID-19 Update for the Week of January 30, 2023

FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

FDA Announces Evusheld is Not Currently Authorized for Emergency Use in the U.S.

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT